- Reported transaction lines
- 2
- Buy lines
- 0
- Sell lines
- 1
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-112
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Apuli Maricel Chief Accounting Officer · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 115973 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,261 shares of Common Stock underlying the Reporting Person's RSUs. | 2026-11-16 | 2026-11-18 | 4,714 shares/units | SEC 4 |
| Apuli Maricel Chief Accounting Officer · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 120687 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. | 2026-10-30 | 2026-11-03 | ≈ $145,700.00 2,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.